Needham Investment Management LLC lowered its position in Tekla Life Sciences Investors (NYSE:HQL) by 1.9% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 539,725 shares of the company’s stock after selling 10,581 shares during the period. Tekla Life Sciences Investors comprises approximately 2.8% of Needham Investment Management LLC’s investment portfolio, making the stock its 11th largest position. Needham Investment Management LLC’s holdings in Tekla Life Sciences Investors were worth $10,595,000 as of its most recent SEC filing.
Separately, Doliver Capital Advisors LP bought a new stake in Tekla Life Sciences Investors in the fourth quarter valued at approximately $350,000. 14.09% of the stock is currently owned by institutional investors.
In other news, Director Thomas M. Kent purchased 1,300 shares of Tekla Life Sciences Investors stock in a transaction that occurred on Thursday, January 25th. The shares were bought at an average cost of $21.04 per share, with a total value of $27,352.00. Following the completion of the purchase, the director now directly owns 1,300 shares in the company, valued at $27,352. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 1.00% of the stock is owned by corporate insiders.
Shares of Tekla Life Sciences Investors (HQL) opened at $19.89 on Wednesday. Tekla Life Sciences Investors has a 12-month low of $18.26 and a 12-month high of $22.24.
The company also recently declared a quarterly dividend, which will be paid on Thursday, March 29th. Investors of record on Wednesday, February 28th will be paid a $0.40 dividend. The ex-dividend date is Tuesday, February 27th. This represents a $1.60 annualized dividend and a yield of 8.04%.
About Tekla Life Sciences Investors
Tekla Life Sciences Investors (the Fund) is a diversified closed-end management investment company. The Fund’s investment objective is long-term capital appreciation through investment in the United States and foreign companies in the life sciences industry, including biotechnology, pharmaceutical, diagnostics, managed healthcare and medical equipment, hospitals, healthcare information technology and services, devices and supplies, agriculture, and environmental management.
Want to see what other hedge funds are holding HQL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tekla Life Sciences Investors (NYSE:HQL).